Search results for "sickle cell disease"

showing 2 items of 2 documents

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Pla…

2019

The reference methods used for sickle cell disease (SCD) screening usually include two analytical steps: a first tier for differentiating haemoglobin S (HbS) heterozygotes, HbS homozygotes and β-thalassemia from other samples, and a confirmatory second tier. Here, we evaluated a first-tier approach based on a fully automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform with automated sample processing, a laboratory information management system and NeoSickle® software for automatic data interpretation. A total of 6701 samples (with high proportions of phenotypes homozygous (FS) or heterozygous (FAS) for the inherited genes for sickle h…

MALDI-TOFPediatricsmedicine.medical_specialtythalassemia[SDV]Life Sciences [q-bio]Sample (statistics)01 natural sciencesArticle03 medical and health sciencesImmunology and Microbiology (miscellaneous)preventionmedicineDisease Screening Procedure030304 developmental biologymass spectrometry0303 health sciencesNewborn screeningbusiness.industryMALDI-TOF; sickle cell disease; newborn screening; mass spectrometry; thalassemia; preventionnewborn screening010401 analytical chemistrylcsh:RJ1-570Obstetrics and GynecologyData interpretationlcsh:Pediatrics0104 chemical sciencesMatrix-assisted laser desorption/ionizationFully automatedSickle haemoglobinPediatrics Perinatology and Child Healthsickle cell diseaseSample collectionbusinessInternational Journal of Neonatal Screening
researchProduct